Example: barber
Other statutory disclosures continued - GSK
Glaxo New Zealand Pension Plan Trustee Limited Ordinary Level 11, Zurich House, 21 Queen Street, Auckland, 1010, New Zealand Glaxo Operations UK Limited Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Glaxo Properties BV Ordinary Huis ter Heideweg 62, 3705 LZ, Zeist, Netherlands
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Annual Report 2019 - GSK
www.gsk.comTrust We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. Our values and expectations Our values – patient focus, transparency, respect and integrity. Our expectations – courage, accountability, development and teamwork.
Emma Walmsley, CEO - gsk.com
www.gsk.comAgenda 2 Q2 2018 progress (15 mins) Emma Walmsley, Chief Executive Officer Q2 2018 financial results (15 mins) Simon Dingemans, Chief Financial Officer
Audit & Risk Committee Terms of Reference - Home | GSK
www.gsk.comAudit & Risk Committee – Terms of Reference 2 3. Each of the members of the Committee shall be independent Non-Executive Directors, as determined by the Board of the Company, in accordance with the provisions of the UK Corporate
Press release Third quarter 2021
www.gsk.comIssued: Wednesday, 27 October 2021, London, U.K. 3 Operating performance – Q3 2021 Turnover Q3 2021 £m Growth £% Growth CER% Pharmaceuticals 4,397 5 10 Vaccines 2,174 7 13 Consumer Healthcare 2,506 3 8 Group turnover 9,077 5 10 Group turnover was £9,077 million in the quarter, up 5% AER, 10% CER.
Q3 2021 results
www.gsk.comProgressing towards demerger at pace. 8. 1. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. 2021-26 CAGR is for the 5 …
Annual Report 2018 - GSK
www.gsk.comGSK Annual Report 2018 02. Research & development . Success in R&D will always be fundamental to shareholder returns. A renewed focus on R&D was set out by Emma Walmsley when she became CEO in 2017, and a new plan to improve the pipeline of new medicines has now been launched by Dr Hal Barron, our new Chief
Press release Full year and fourth quarter 2020 - GSK
www.gsk.com* Reported AER and CER growth rates for 2020 include five months’ results of the former Pfizer consumer healthcare business in 2019. Pro-forma CER growth rates are calculated as if the equivalent seven months of Pfizer consumer healthcare business results, as reported by Pfizer, were included in the comparative period of 2019.
Financial statements - GSK
www.gsk.comThe Group financial statements for the year ended . 31 December 2020, comprising principal statements and supporting notes, are set out in the ‘Financial statements’ on pages 154 to 237 of this report. The parent company financial statements for the year ended 31 December 2020, comprising the balance sheet and the statement of changes in
Annual Report 2020 - GSK
www.gsk.comframework, we invest in our business to provide shareholder returns. In 2020 we paid a dividend of 80p per share and delivered £5.4 billion of free cash flow. We make a positive contribution to the communities in . which we operate. We employ over 94,000 people across 96 countries and work directly with 36,000 suppliers.
ESG Performance Summary 2020 - GSK
www.gsk.comEmployee turnover Overall turnover (%) – – 12.5 15.7 Calculated as the number of permanent employees that left GSK in 2020 for any reason divided by the average 2020 permanent headcount. Turnover of voluntary leavers (%) – – 6.7 5.6 Calculated as the number of permanent employees that voluntarily left GSK in 2020
Related documents
ADMINISTRATION PROCESS AND PROCEDURE
www.fieldslaw.co.za* ordinary residence for past 12 months * income tax number ... you will need to complete an acceptance of trust as executor form (in duplicate) if the estate is worth less than r125.000-00 (section 18(3)) ... - where the estate is dutiable for jse shares request from stock broker – value of all shares as at date of death